Arbutus Biopharma Corp ABUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech — Update
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech
Arbutus Biopharma Gets FDA Fast-Track Designation for Imdusiran in Chronic Hepatitis B
Trading Information
- Previous Close Price
- $4.03
- Day Range
- $3.92–4.14
- 52-Week Range
- $3.50–5.45
- Bid/Ask
- $3.98 / $4.19
- Shares Outstanding
- 153.29M
- Market Cap
- $626.97M
- Volume/Avg
- 3M / 5M
Key Statistics
- Price/Earnings (Normalized)
- 9.85
- Price/Sales
- 4.42
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 19
- Website
- http://www.arbutusbio.com
Valuation
Metric | ABUS |
|---|---|
Price/Earnings (Normalized) | 9.85 |
Price/Book Value | 9.51 |
Price/Sales | 4.42 |
Price/Cash Flow | 3.64 |
Price/Earnings
ABUS
Financial Strength
Metric | ABUS |
|---|---|
Quick Ratio | 1.40 |
Current Ratio | 1.40 |
Interest Coverage | 3,360.48 |
Quick Ratio
ABUS
Profitability
Metric | ABUS |
|---|---|
Return on Assets (Normalized) | 102.55% |
Return on Equity (Normalized) | 146.43% |
Return on Invested Capital (Normalized) | 143.47% |
Return on Assets
ABUS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|MfG$p^ | LOCK|Rjh> | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|N#S?#$g | LOCK|Rqx@ | $99B | |||
| Moderna Inc MRNA | LOCK|Kpt@$& | LOCK|gNZ | $90B | |||
| argenx SE ADR ARGX | LOCK|!WT<n# | LOCK|<@ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|B%VqSF | LOCK|x#S | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|H#?fqzWt | LOCK|$>hx | $31B | |||
| Incyte Corp INCY | LOCK|MV&<cc | LOCK|%yZ | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|@Z<XNMc | LOCK|>pBX | $22B | |||
| BioNTech SE ADR BNTX | LOCK|@^JC#D | LOCK|&% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|v&x<cmx | LOCK|t< | $16B |
United States